Arterial Age Screening for Hidden Cardiovascular Risk: A Scientific Review

Abstract

Arterial age screening has emerged as a valuable tool to detect and quantify hidden cardiovascular risk, bridging the gap between chronological age and underlying vascular health. This review synthesizes current evidence, focusing on the clinical utility, pathophysiological rationale, and practical implications of arterial age assessment in cardiovascular risk stratification. Emphasis is placed on the integration of arterial age into clinical workflows, the epidemiological impact of subclinical atherosclerosis detection, and recent advances in non-invasive vascular imaging. The article also discusses guideline recommendations and highlights areas for future research.

Introduction

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide, often progressing silently until manifesting as acute clinical events. Traditional risk stratification models, while useful, may underestimate risk in certain populations by relying solely on chronological age and classical risk factors. Arterial age, defined as the biological age of the vasculature as opposed to the patient's actual age, offers a more individualized assessment of vascular health. By quantifying subclinical atherosclerosis and arterial stiffness, arterial age screening has the potential to unmask hidden cardiovascular risk and refine preventive strategies in clinical practice.

Epidemiology / Disease Burden

The global burden of CVD is immense, accounting for over 17 million deaths annually. A significant proportion of individuals who suffer from myocardial infarction or stroke have no prior symptoms and may be classified as low- or intermediate-risk by conventional algorithms. Epidemiological studies indicate that up to 50% of cardiovascular events occur in individuals who would not have qualified for intensive preventive interventions based on traditional risk scoring systems. Subclinical vascular damage, as detected by arterial age screening, is prevalent even in asymptomatic adults, signifying a substantial hidden burden and missed opportunities for early intervention.

Pathophysiology

Arterial age reflects cumulative exposure to cardiovascular risk factors and the resultant biological changes in the arterial wall, including endothelial dysfunction, intimal thickening, calcification, and increased arterial stiffness. These alterations accelerate the atherosclerotic process and impair vascular compliance, ultimately predisposing individuals to clinical events. The discrepancy between arterial and chronological age is particularly pronounced in patients with metabolic syndrome, diabetes, chronic kidney disease, and certain genetic predispositions. Mechanistically, the progression of arterial aging involves oxidative stress, chronic inflammation, and dysregulated repair mechanisms, all of which contribute to accelerated vascular senescence and heightened cardiovascular risk.

Risk Factors

Traditional cardiovascular risk factors such as hypertension, hyperlipidemia, diabetes mellitus, smoking, and obesity strongly influence arterial aging. Non-traditional factors, including chronic inflammation, sedentary lifestyle, air pollution, and psychosocial stress, have also been implicated. Genetic determinants, particularly those affecting lipid metabolism and arterial wall integrity, further modulate the rate of arterial aging. Importantly, there is growing recognition of the role of early-life exposures and epigenetic modifications in setting the trajectory of arterial health across the lifespan.

Clinical Features

Subclinical arterial aging is typically asymptomatic, with clinical features manifesting only after significant vascular compromise. However, in certain cases, physical examination may reveal signs of arterial stiffness, such as widened pulse pressure or diminished peripheral pulses. More commonly, the identification of advanced arterial age occurs through imaging or non-invasive vascular testing, often preceding overt clinical events. Recognizing individuals with discordant arterial and chronological age is critical, as they represent a high-risk group for future cardiovascular events despite being asymptomatic.

Diagnosis

The assessment of arterial age can be performed using several non-invasive modalities. Carotid intima-media thickness (CIMT) measured by ultrasound, coronary artery calcium (CAC) scoring via computed tomography, and pulse wave velocity (PWV) are validated techniques for estimating vascular age. Each modality offers unique insights: CIMT reflects early atherosclerotic changes, CAC quantifies calcified plaque burden, and PWV assesses arterial stiffness. Integrating arterial age into risk prediction models, such as the Framingham Risk Score or ASCVD calculators, has been shown to improve risk stratification, particularly in intermediate-risk populations. The choice of modality should be individualized based on patient characteristics, resource availability, and clinical context.

Treatment & Management

Identifying an elevated arterial age prompts a re-evaluation of preventive strategies. Management focuses on aggressive modification of cardiovascular risk factors, including initiation or intensification of antihypertensive, lipid-lowering, and antidiabetic therapies as appropriate. Lifestyle interventions encompassing dietary optimization, regular physical activity, smoking cessation, and weight management are foundational. In select cases, aspirin or other antithrombotic agents may be considered, guided by individual risk profiles. Shared decision-making and patient education are essential to ensure adherence and address concerns regarding asymptomatic disease.

Recent Advances / Emerging Therapies

Technological advancements have facilitated more accurate and accessible measurements of arterial age. Novel biomarkers, such as circulating endothelial progenitor cells, microRNAs, and advanced glycation end-products, are being investigated as adjuncts to imaging-based assessments. Artificial intelligence and machine learning algorithms are enabling automated analysis of vascular imaging, increasing efficiency and reproducibility. Emerging pharmacotherapies targeting vascular inflammation and senescence pathways hold promise for decelerating arterial aging and reducing cardiovascular risk beyond conventional risk factor modification.

Guideline Recommendations

Recent clinical guidelines, including those from the American Heart Association and European Society of Cardiology, acknowledge the value of arterial age assessment in selected populations. Recommendations emphasize the use of arterial imaging or vascular function testing in intermediate-risk individuals, those with a family history of premature CVD, or when there is uncertainty regarding risk categorization. The integration of arterial age into shared decision-making is encouraged, with the caveat that screening should be tailored to individual patient profiles and local resource availability. Ongoing research is required to define optimal thresholds and screening intervals for various subgroups.

Conclusion

Arterial age screening represents a paradigm shift in cardiovascular risk assessment, enabling the early detection of subclinical vascular disease and identification of individuals at heightened risk for future events. By transcending the limitations of chronological age and traditional risk scores, arterial age assessment provides a more nuanced and personalized approach to prevention. Continued research, technological innovation, and the development of clear clinical pathways will be essential to fully realize the potential of arterial age screening in mitigating the global burden of cardiovascular disease.